...
首页> 外文期刊>American Journal of Physiology >Chronic antihypertensive treatment improves pulse pressure but not large artery mechanics in a mouse model of congenital vascular stiffness
【24h】

Chronic antihypertensive treatment improves pulse pressure but not large artery mechanics in a mouse model of congenital vascular stiffness

机译:慢性抗高血压治疗改善了先天性血管刚度的小鼠模型中的脉压但不是大动脉力学

获取原文
获取原文并翻译 | 示例

摘要

Halabi CM, Broekelmann TJ, Knutsen RH, Ye L, Mecham RP, Increased arterial stiffness is a common characteristic of humans with Williams-Beuren syndrome and mouse models of elastin insufficiency. Arterial stiffness is associated with multiple negative cardiovascular outcomes, including myocardial infarction, stroke, and sudden death. Therefore, identifying therapeutic interventions that improve arterial stiffness in response to changes in elastin levels is of vital importance. The goal of this study was to determine the effect of chronic pharmacologic therapy with different classes of antihypertensive medications on arterial stiffness in elastin insufficiency. Elastin-insufficient mice 4-6 wk of age and wild-type littermates were subcutaneously implanted with osmotic micropumps delivering a continuous dose of one of the following: vehicle, losartan, nicardipine, or propranolol for 8 wk. At the end of treatment period, arterial blood pressure and large artery compliance and remodeling were assessed. Our results show that losartan and nicardipine treatment lowered blood pressure and pulse pressure in elastin-insufficient mice. Elastin and collagen content of abdominal aortas as well as ascending aorta and carotid artery bio-mechanics were not affected by any of the drug treatments in either genotype. By reducing pulse pressure and shifting the working pressure range of an artery to a more compliant region of the pressure-diameter curve, antihypertensive medications may mitigate the consequences of arterial stiffness, an effect that is drug class independent. These data emphasize the importance of early recognition and long-term management of hypertension in Williams-Beuren syndrome and elastin insufficiency.
机译:Halabi cm,Broekelmann Tj,Knutsen Rh,Ye L,Mecham Rp,增加的动脉僵硬是人类患有威廉姆斯 - Beuren综合征和Elastin功能不全的小鼠模型的常见特征。动脉僵硬与多个阴性心血管结果相关,包括心肌梗死,中风和猝死。因此,鉴定治疗干预措施,以应对弹性蛋白水平的变化改善动脉僵硬度至关重要。本研究的目的是确定慢性药物治疗与不同类别的抗高血压药物对弹性素不足的动脉僵硬的影响。皮下植入弹性蛋白不足的小鼠4-6周和野生型凋落物,渗透渗透微型泵,其连续剂量是下列:载体,氯沙坦,尼加丁或普萘洛尔8周。在治疗期结束时,评估动脉血压和大动脉依从性和重塑。我们的研究结果表明,氯沙坦和Nicardipine治疗降低了弹性蛋白不足小鼠中的血压和脉压。腹部主动脉的弹性蛋白和胶原蛋白含量以及升高的主动脉和颈动脉生物力学不受任何一种基因型中的任何药物治疗的影响。通过减少脉冲压力并将动脉的工作压力范围转移到更符合的压力直径曲线的区域,抗高血压药物可能会减轻动脉僵硬的后果,其效果是无关的。这些数据强调了早期识别和长期管理威廉姆斯 - 贝仑综合征和弹性素不足的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号